deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05194982

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Conditions Locally Advanced or Metastatic Solid Tumor
Interventions BL-B01D1
Updated 13 times since 2022 Last updated: Sep 25, 2025 Started: Nov 29, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05194982, this PHASE1 trial focuses on Locally Advanced or Metastatic Solid Tumor and remains actively recruiting participants. Sponsored by Sichuan Baili Pharmaceutical Co., Ltd., it has been updated 13 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jan 2024 · 9 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Jun 2025 · 5 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  3. Jun 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  4. Jan 2025 — Jun 2025 [monthly]

    Recruiting PHASE1

  5. Oct 2024 — Jan 2025 [monthly]

    Recruiting PHASE1

▶ Show 8 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

  4. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jan 2024 — May 2024 [monthly]

    Recruiting PHASE1

  6. Apr 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  7. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  8. Feb 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • SystImmune Inc.
Data source: Sichuan Baili Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations